← Evidence map

ArticleRheumatology and therapy2026

Olokizumab Improves Patient-Reported Outcomes in Patients with Active Rheumatoid Arthritis up to 106 Weeks (Results from the Open-Label Extension of Phase III Randomized Clinical Trials).

Roy M Fleischmann et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

Not cited yet

5 trials

NCT02760368phase 3428 enrolled2016 NCT02760407phase 31,648 enrolled2016 NCT02760433phase 3368 enrolled2017 NCT03120949phase 32,106 enrolled2017 NCT03225932

Olokizumab Improves Patient-Reported Outcomes in Patients with Active Rheumatoid Arthritis up to 106 Weeks (Results from the Open-Label Extension of Phase III Randomized Clinical Trials). | OpenQuestion